Physician profile
Paul Drambarean
NPI 1033344734
$1,293.59
in general payments reported to CMS, 2019-2025
15 companies · $99.77 in 2025
The $99.77 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $68.75 · 2021: $115 · 2022: $160 · 2023: $213 · 2024: $226 · 2025: $99.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.60 | 2021-2025 | Teflaro, Avycaz, Dalvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.39 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $186.96 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $144.96 | 2019-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $127.72 | 2019-2020 | |
| Allergan, INC. | $114.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $55.52 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.60 | 2019 | |
| Viatris Specialty LLC | $45.61 | 2025 | Yupelri |
| Pfizer INC. | $45.46 | 2019-2024 | |
| Gilead Sciences, INC. | $31.32 | 2024 | |
| Mylan Specialty L.P. | $21.40 | 2024 | Yupelri |
| Inari Medical, INC. | $20.75 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medimetriks Pharmaceuticals, INC. | $19.44 | 2025 | |
| Atricure, INC. | $16.72 | 2025 | Synergy Ablation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Drambarean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.